Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Free Cash Flow (2018 - 2026)

10x Genomics' Free Cash Flow history spans 8 years, with the latest figure at $40.7 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 2479.02% to $40.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $135.8 million, a 2456.65% increase, with the full-year FY2025 number at $135.8 million, up 2456.65% from a year prior.
  • Free Cash Flow hit $40.7 million in Q4 2025 for 10x Genomics, down from $46.6 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TXG hit a ceiling of $67.6 million in Q4 2023 and a floor of -$92.4 million in Q3 2021.
  • Historically, Free Cash Flow has averaged -$8.3 million across 5 years, with a median of -$3.6 million in 2023.
  • Biggest five-year swings in Free Cash Flow: tumbled 697.23% in 2021 and later surged 2479.02% in 2025.
  • Tracing TXG's Free Cash Flow over 5 years: stood at -$21.8 million in 2021, then plummeted by 306.4% to -$88.6 million in 2022, then soared by 176.24% to $67.6 million in 2023, then crashed by 97.67% to $1.6 million in 2024, then surged by 2479.02% to $40.7 million in 2025.
  • Business Quant data shows Free Cash Flow for TXG at $40.7 million in Q4 2025, $46.6 million in Q3 2025, and $16.1 million in Q2 2025.